Xiaojing Wang is currently a Senior Scientist in the Department of Discovery Chemistry at Genentech. In the past 6 years, Xiaojing has led multidisciplinary teams into nominating several clinical candidates as a project team lead. She also contributed to the early discovery of an orally bioavailable BTK inhibitor currently in Phase II clinical trials. Prior to Genentech, Xiaojing has pursued drug discovery of various disease indications at ISIS (now Ionis) and Scios/Johnson and Johnson. Xiaojing received B.S. and Ph.D. degrees in chemistry from Peking University and the University of Florida, and was a Postdoctoral Fellow at RTI International. Xiaojing has been invited as a speaker at national and international conferences and chaired a symposium at the 2016 American Chemical Society National Meeting. Xiaojing is an inventor and author of over 40 patents and research publications. Her recent article in ACS Medicinal Chemistry Letters regarding the discovery of BTK inhibitors was selected to be a featured article by the editors.